Mind Medicine (MindMed) Beat Consensus Estimates
Thursday, May 8, 2025 at 7:00 AM ET
Mind Medicine (MindMed) (MNMD) reported a loss of $0.35 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.36 per share. The company beat consensus estimates by 2.78%.
Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine Inc. is based in New York, United States.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.35
Earnings Whisper®
-
Consensus Estimate
$-0.36
Earnings Surprise
Earnings Growth
Reported Revenue
-
Revenue Estimate
-
Revenue Surprise
Revenue Growth